Budget & Taxes

SB 247 converts Maryland's Biotechnology Investment Incentive Tax Credit into a direct grant program administered by the Department of Commerce. It replaces tax credits with cash grants for qualifying biotechnology companies engaged in research, development, or commercialization of biological technologies. The bill requires the Department to disburse grants within a specified timeframe and allows recipients to deduct these grants from their Maryland income tax for the same year. This change shifts the incentive from tax savings to immediate funding, directly affecting eligible biotech firms in Maryland.

SB 283 authorizes Maryland to borrow $1.824 billion through a new 2026 capital bond loan, updating previous bond programs from 2015-2025. The funds will finance state construction, renovations, equipment, and grants to local governments for infrastructure projects, requiring matching local funds and strict spending deadlines. It modifies prior bond law provisions to clarify eligible uses, extend project timelines, and adjust budget allocations for ongoing capital projects. This bill primarily affects state agencies, local governments receiving grants, and public infrastructure projects across Maryland.